olivLaw · US equity research
Enovis Corporation ENOV
Orthopedic, Prosthetic & Surgical Appliances & Supplies · SIC 3842 · Vertical: Orthopedic, Prosthetic & Surgical Appliances & Supplies (SIC 3842)
Enovis is a medical technology company that designs and distributes orthopedic devices, from prevention and recovery products to implants for reconstructive joint surgery. The company is in a restructuring phase after goodwill impairments in 2025, and first-half 2026 shows a modest sales recovery with annual revenue guidance reaffirmed at about 2.33 billion USD.
At the close of 04 Nov 2026, Enovis Corporation (ENOV) stock was 24.42 USD (+16.90% on the day), with market capitalisation 1.4 bn USD, beta 1.47, 52-week range 17.43–31.51 USD. Latest reported quarter (Q2 2026): revenue of 582.8 m USD (+3.2% YoY), net income of -1.2 m USD, diluted EPS -0.02 USD.
Data as of · AI analysis dated · Source: SEC filings and closing prices, computed by olivLaw.
Price history
Loading chart…
Technical reading
- RSI (14)
- 67.5
- strong (55–70)
- Bollinger (20, 2)
- 16.98 – 23.73
- above the upper band · %B 1.10 · band width 33.1%
- SMA 50 / 200
- 19.79 / 23.05
- mixed trend
- MACD (12, 26, 9)
- 0.73 / 0.44
- MACD above signal
Indicators describe past prices; on their own they do not predict direction. On our history the RSI ≤ 40 filter added no return (see the signals methodology).
Performance
| Company | S&P 500 | vs S&P 500 | Vertical median | |
|---|---|---|---|---|
| 1 month | +30.7% | −1.1% | +31.8 pp | — |
| 3 months | −19.1% | −0.5% | −18.6 pp | — |
| 6 months | −1.7% | +4.4% | −6.1 pp | — |
| Year to date | −8.3% | +12.3% | −20.6 pp | — |
| 1 year | −22.3% | +13.5% | −35.9 pp | +2.0% |
| 3 years | −48.1% | +76.4% | −124.5 pp | −0.2% |
| 5 years | −73.2% | +63.7% | −136.9 pp | — |
Price returns, dividends excluded.
Quarterly results
Latest quarter: Q2 2026 · 03 Jul 2026
Quarterly margins
Quarterly statements · USD
| Fiscal year | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | Q2 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 505.2 m | 561.0 m | 558.8 m | 564.5 m | 548.9 m | 575.8 m | 589.2 m | 582.8 m |
| Cost of revenue | 218.8 m | 253.5 m | 226.6 m | 229.8 m | 220.0 m | 226.3 m | 223.7 m | 223.5 m |
| Gross profit | 286.5 m | 307.5 m | 332.2 m | 334.7 m | 328.9 m | 349.4 m | 365.5 m | 359.2 m |
| Research & development | 20.5 m | 24.0 m | 28.5 m | 30.7 m | 29.7 m | 31.4 m | 31.5 m | 31.7 m |
| SG&A | 249.9 m | 257.7 m | 269.0 m | 267.1 m | 263.6 m | 270.4 m | 282.8 m | 263.7 m |
| Operating income | -31.7 m | -664.7 m | -46.8 m | -16.8 m | -558.5 m | -502.2 m | 6.5 m | 17.4 m |
| Depreciation & amortisation | 71.2 m ≈ | 717.4 m | 71.4 m | 71.6 m ≈ | 74.4 m ≈ | 1.1 bn | 73.4 m | 71.0 m ≈ |
| Interest expense | 11.1 m | 9.1 m | 9.2 m | 9.3 m | 8.8 m | 7.5 m | 9.2 m | 8.0 m |
| Pre-tax income | -42.6 m | -673.7 m | -57.3 m | -25.7 m | -566.9 m | -509.5 m | 634.0 k | 7.5 m |
| Income tax | -9.1 m | 29.9 m | -1.8 m | 10.8 m | 4.0 m | 9.3 m | 9.0 m | 8.5 m |
| Net income | -31.5 m | -703.3 m | -56.0 m | -36.7 m | -571.1 m | -520.6 m | -8.8 m | -1.2 m |
| Diluted EPS | -0.58 | -12.59 ≈ | -0.98 | -0.64 | -9.99 | -9.10 ≈ | -0.15 | -0.02 |
| Operating cash flow | 53.6 m ≈ | 88.3 m | -1.6 m | 47.8 m ≈ | 82.6 m ≈ | 88.5 m | 24.0 m | 75.0 m ≈ |
| Capex | 51.2 m ≈ | 53.2 m | 43.3 m | 44.4 m ≈ | 53.5 m ≈ | 56.3 m | 52.8 m | 43.9 m ≈ |
≈ derived quarter (cumulative difference / share-days average)
E/P over time
E/P = trailing-12-month diluted EPS / price at quarter end. E/P is the inverse of P/E and stays defined when earnings are negative.
Fiscal years
| Fiscal year | 2018 | 2019 | ⚠ 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 2.2 bn | 3.3 bn | 1.1 bn | 1.4 bn | 1.6 bn | 1.7 bn | 2.1 bn | 2.2 bn |
| Revenue YoY | +13.2% | +51.7% | — | +27.3% | +9.6% | +9.2% | +23.5% | +6.7% |
| Net income | 140.2 m | -527.6 m | 42.6 m | 71.7 m | -13.3 m | -33.3 m | -825.5 m | -1.2 bn |
| Net income YoY | −7.2% | −476.4% | — | +68.1% | −118.5% | unavailable | unavailable | unavailable |
| Diluted EPS | 1.16 | -3.89 | 0.93 | 1.40 | -0.25 | -0.61 | -14.93 | -20.75 |
| Diluted EPS YoY | −4.9% | −435.3% | — | +50.5% | −117.9% | unavailable | unavailable | unavailable |
| net % | 6.4% | -15.9% | 3.8% | 5.0% | -0.9% | -1.9% | -39.2% | -52.7% |
| Free cash flow | 156.7 m | 5.5 m | 187.2 m | 251.9 m | -161.3 m | 12.8 m | -67.2 m | 19.9 m |
The series breaks before 2020: earlier years come from the original reports of the issuer of that time, later years from a subsequent filing that restated the perimeter (a separation, discontinued operations). The year-on-year change across the break is not shown.
Reported results vs expectations
Loading…
Balance sheet & financial health
Fiscal year 2025 · 31 Dec 2025
- Cash
- 36.4 m USD
- Financial debt
- 1.3 bn USD
- Net debt
- 1.3 bn USD
- Equity
- 1.5 bn USD
- Total assets
- 3.8 bn USD
- Debt / equity
- 0.87x
- Current ratio
- 2.02x
- ROE
- -58.4%
- ROA
- -27.7%
- FCF margin
- 0.9%
Financial statements (source on every figure)
Revenue and net income (USD)
Margins
Income statement · USD
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Revenue | 1.1 bn | 1.4 bn | 1.6 bn | 1.7 bn | 2.1 bn | 2.2 bn | SEC (XBRL)· 26 Feb 2026verified |
| Cost of revenue | 517.1 m | 648.5 m | 693.7 m | 716.4 m | 926.9 m | 902.8 m | SEC (XBRL)· 26 Feb 2026verified |
| Gross profit | 603.6 m | 777.7 m | 869.4 m | 990.8 m | 1.2 bn | 1.3 bn | SEC (XBRL)· 26 Feb 2026verified |
| Research & development | 34.3 m | 49.1 m | 60.8 m | 75.3 m | 91.3 m | 120.3 m | SEC (XBRL)· 26 Feb 2026verified |
| SG&A | 515.5 m | 665.8 m | 772.9 m | 830.3 m | 1.0 bn | 1.1 bn | SEC (XBRL)· 26 Feb 2026verified |
| Operating income | -66.2 m | -62.8 m | -71.2 m | -65.7 m | -775.7 m | -1.1 bn | SEC (XBRL)· 26 Feb 2026verified |
| Depreciation & amortisation | 167.9 m | 187.0 m | 203.0 m | 217.1 m | 927.8 m | 1.3 bn | SEC (XBRL)· 26 Feb 2026verified |
| EBITDA | 101.7 m ≈ | 124.2 m ≈ | 131.8 m ≈ | 151.4 m ≈ | 152.1 m ≈ | 219.9 m ≈ | SEC (XBRL)· 26 Feb 2026derived |
| Interest expense | 52.8 m | 29.1 m | 24.1 m | 19.7 m | 57.1 m | 34.8 m | SEC (XBRL)· 26 Feb 2026verified |
| Pre-tax income | -119.0 m | -121.8 m | -2.1 m | -67.1 m | -822.9 m | -1.2 bn | SEC (XBRL)· 26 Feb 2026verified |
| Income tax | -44.6 m | -19.5 m | 36.1 m | -13.3 m | 4.5 m | 22.3 m | SEC (XBRL)· 26 Feb 2026verified |
| Net income | 42.6 m | 71.7 m | -13.3 m | -33.3 m | -825.5 m | -1.2 bn | SEC (XBRL)· 26 Feb 2026verified |
| Diluted EPS | 0.93 | 1.40 | -0.25 | -0.61 | -14.93 | -20.75 | SEC (XBRL)· 26 Feb 2026verified |
| Weighted average diluted shares | 45.6 m | 51.1 m | 54.1 m | 54.5 m | 55.3 m | 57.1 m | SEC (XBRL)· 26 Feb 2026verified |
≈ computed by olivLaw from the reported lines of the same year: Operating income + Depreciation & amortisation.
Balance sheet · USD
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Cash | 97.1 m | 680.3 m | 24.3 m | 36.2 m | 48.2 m | 36.4 m | SEC (XBRL)· 26 Feb 2026verified |
| Receivables | 517.0 m | 255.0 m | 267.4 m | 291.5 m | 407.0 m | 442.8 m | SEC (XBRL)· 26 Feb 2026verified |
| Inventories | 564.8 m | 356.2 m | 426.6 m | 468.8 m | 547.1 m | 584.4 m | SEC (XBRL)· 26 Feb 2026verified |
| Current assets | 1.4 bn | 2.3 bn | 795.0 m | 896.5 m | 1.1 bn | 1.2 bn | SEC (XBRL)· 26 Feb 2026verified |
| Property, plant & equipment, net | 487.0 m | 235.1 m | 236.7 m | 270.8 m | 404.5 m | 507.1 m | SEC (XBRL)· 26 Feb 2026verified |
| Goodwill | 1.8 bn | 1.9 bn | 2.0 bn | 2.1 bn | 1.7 bn | 718.3 m | SEC (XBRL)· 26 Feb 2026verified |
| Intangibles (excl. goodwill) | 1.7 bn | 1.2 bn | 1.1 bn | 1.1 bn | 1.3 bn | 1.2 bn | SEC (XBRL)· 26 Feb 2026verified |
| Total assets | 7.4 bn | 8.5 bn | 4.3 bn | 4.5 bn | 4.7 bn | 3.8 bn | SEC (XBRL)· 26 Feb 2026verified |
| Accounts payable | 330.3 m | 155.2 m | 135.6 m | 132.5 m | 179.1 m | 187.5 m | SEC (XBRL)· 26 Feb 2026verified |
| Short-term debt | 27.1 m | 7.7 m | 219.3 m | 0 | 20.0 m | 35.0 m | SEC (XBRL)· 26 Feb 2026verified |
| Long-term debt | 2.2 bn | 2.1 bn | 40.0 m | 466.2 m | 1.3 bn | 1.3 bn | SEC (XBRL)· 26 Feb 2026verified |
| Current liabilities | 811.7 m | 1.0 bn | 565.2 m | 369.6 m | 529.0 m | 598.5 m | SEC (XBRL)· 26 Feb 2026verified |
| Total liabilities | 3.8 bn | 3.9 bn | 823.4 m | 1.1 bn | 2.2 bn | 2.3 bn | SEC (XBRL)· 26 Feb 2026verified |
| Equity | 3.6 bn | 4.7 bn | 3.4 bn | 3.4 bn | 2.6 bn | 1.5 bn | SEC (XBRL)· 26 Feb 2026verified |
| Shares outstanding at year end | 118.5 m | — | — | — | — | — | SEC (XBRL)· 18 Feb 2021verified |
Cash flow · USD
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Operating cash flow | 301.9 m | 356.1 m | -55.9 m | 135.0 m | 113.5 m | 217.3 m | SEC (XBRL)· 26 Feb 2026verified |
| Capex | 114.8 m | 104.2 m | 105.5 m | 122.2 m | 180.7 m | 197.4 m | SEC (XBRL)· 26 Feb 2026verified |
| Free cash flow | 187.2 m ≈ | 251.9 m ≈ | -161.3 m ≈ | 12.8 m ≈ | -67.2 m ≈ | 19.9 m ≈ | SEC (XBRL)· 26 Feb 2026derived |
| Investing cash flow | -175.1 m | -320.5 m | -176.4 m | -242.5 m | -955.5 m | -179.4 m | SEC (XBRL)· 26 Feb 2026verified |
| Financing cash flow | -131.7 m | 584.9 m | -465.1 m | 127.8 m | 846.8 m | -52.4 m | SEC (XBRL)· 26 Feb 2026verified |
| Share repurchases | 0 | — | 0 | 0 | 4.8 m | 3.5 m | SEC (XBRL)· 26 Feb 2026verified |
≈ computed by olivLaw from the reported lines of the same year: Operating cash flow − Capex.
Computed indicators
Growth
Profitability
Returns
Balance sheet
Liquidity
Cash
Efficiency
Market and valuation
1 indicators that do not apply to the sector.
Valuation
olivLaw classification
Score: 45 / 100
A scoring methodology on indicators and valuation, not investment advice.
Closing price
04 Nov 2026Source: olivLaw, closing series
Market cap: 1.4 bn USD
Key indicators
Coverage and freshness
Score by group
- Valuation81
- Balance sheet27
- Quality16
- Growth100
- Returns4
Estimated value range
The combined range = the median of the valid methods' low, central and high values; it is not a probability interval and does not cover every result. Envelope of all methods: 11.31 – 120.21 USD.
Valuation assumptions are editorial choices, not measured; beta is not measured.
Method ranges (USD per share)
— — Mid · ▏ Price
Valuation methods
- DCF (discounted cash flow)11.31 – 40.11 (Mid 21.20)WACC 7.3% · starting FCFF 91.8 m USD · terminal value share of EV 80%The WACC × g sensitivity gives the method's bounds; these are not probabilities.Reverse DCF: starting growth implied by the price (fading linearly to terminal growth, everything else fixed): 16.2%
- Peers: EV/EBITDA62.27 – 120.21 (Mid 63.59)6 companies used · median multiple 16.0x · quartiles 15.7x – 26.6xCDRE, EW, MSA, SMTI, STE, ZBH
- Peers: P/Eunavailable · the base of the ratio is not positive
- Dividend discount (DDM)unavailable · input data missing
Classification (SIC) comparables group by industry code, not by economic activity; the direct group is an editorial selection by activity. Members' multiples are on their own trailing twelve months, at their own latest close.
Assumptions (illustrative, editorial)
- Risk-free rate
- 4.3%
- Equity risk premium
- 5.0%
- Beta (default)
- 1.00
- Cost of equity
- 9.3%
- Terminal growth
- 2.5%
Factor scorecard
Neutral profile · Score 45/100
| Factor | Value | Score | Weight used |
|---|---|---|---|
| ROIC · Quality | -26.1% | 9 (vs peers) | 15% |
| Net margin · Quality | -48.0% | 27 (vs peers) | 9% |
| FCF conversion · Quality | unavailable | unavailable | — |
| Revenue CAGR 3Y · Growth | 12.9% | 100 (on a fixed band) | 12% |
| EPS CAGR 3Y · Growth | unavailable | unavailable | — |
| Net debt / EBITDA · Balance sheet | 4.1x | 14 (vs peers) | 15% |
| Interest coverage · Balance sheet | -30.9x | 0 (on a fixed band) | 9% |
| Current ratio · Balance sheet | 2.0x | 99 (on a fixed band) | 6% |
| P/E (TTM) · Valuation | unavailable | unavailable | — |
| EV/EBITDA · Valuation | 8.7x | 100 (vs peers) | 15% |
| FCF yield · Valuation | 4.5% | 57 (on a fixed band) | 12% |
| Shareholder yield (distributions) · Returns | 0.2% | 4 (on a fixed band) | 9% |
| Payout ratio (FCF) · Returns | unavailable | unavailable | — |
Factors without a value were dropped; the remaining weights were renormalised.
Score groups
- Balance sheet27/100 · 3/3 factors with a value
- Growth· partial100/100 · 1/2 factors with a value
- Quality16/100 · 2/3 factors with a value
- Returns· partial4/100 · 1/2 factors with a value
- Valuation81/100 · 2/3 factors with a value
A «partial» group is computed from under half of its weight or from one factor: it is not a full assessment of the group.
Memo
Enovis Corp (ENOV). Latest full fiscal year: 2025; data up to 2026-07-03.
Figures computed from the financial statements: revenue 2.2 bn USD in 2025; YoY growth 6.7%; net margin -48.0%; ROE -54.3%; net debt/EBITDA 4.1x.
The estimated value range is 36.79–80.16 USD per share (median of 2 methods, agreement: low); assumptions are illustrative. Against the central value of 42.39 USD, the price of 24.42 USD leaves a potential of 73.6% (value / price − 1) and a margin of safety of 42.4% (1 − price / value). The range is the median of the methods' low, central and high values, not a probability interval.
olivLaw score 45/100, methodological classification: neutral profile (score, margin of safety and method agreement together; not a judgement of the right price). Groups assessed only in part: growth, returns. Not investment advice.
Text generated deterministically from the figures shown; no language model. Not investment advice.
What supports the thesis
- Revenue CAGR 3Y: 12.9%
- Current ratio: 2.0x
- EV/EBITDA: 8.7x
- The price is below the estimated value range
What contradicts it
- ROIC: -26.1%
- Net margin: -48.0%
- Net debt / EBITDA: 4.1x
- Interest coverage: -30.9x
- Shareholder yield (distributions): 0.2%
- The valuation methods diverge
Not assessed (insufficient data or a ratio without meaning): FCF conversion, EPS CAGR 3Y, P/E (TTM), Payout ratio (FCF).
Versus the vertical median
Orthopedic, Prosthetic & Surgical Appliances & Supplies (SIC 3842) · same industry (4-digit SIC) · compared with 23 companies
Multiples and returns vs the median
Price rebased to 100 (monthly, 5 years)
Companies in the vertical
| Market cap | P/E | ROE | Net margin | Revenue YoY | 1A / 3A | |
|---|---|---|---|---|---|---|
| ISRGIntuitive Surgical, Inc. | 167.1 bn | 58.3 | 18.0% | 25.5% | +20.5% | −16% / +55% |
| EWEdwards Lifesciences Corporation | 57.1 bn | 56.2 | 9.7% | 15.3% | +11.5% | +15% / +47% |
| SNNSmith & Nephew plc | 28.5 bn | 45.3 | 11.8% | 10.1% | +6.1% | −2% / +25% |
| STESTERIS plc | 24.2 bn | 30.0 | 11.4% | 13.3% | +8.7% | −7% / +23% |
| ZBHZimmer Biomet Holdings, Inc. | 20.8 bn | 27.9 | 6.0% | 9.0% | +7.2% | +13% / −5% |
| ALGNAlign Technology, Inc. | 11.6 bn | 24.0 | 11.9% | 11.8% | +0.9% | +12% / −23% |
| MSAMsa Safety Inc | 6.8 bn | 22.8 | 22.1% | 15.0% | +3.7% | +10% / +2% |
| ESTAEstablishment Labs Holdings Inc. | 2.0 bn | — | -175.3% | -15.8% | +27.1% | −3% / +161% |
| ENOVEnovis Corp | 1.4 bn | — | -54.3% | -48.0% | +6.7% | −22% / −48% |
| CDRECadre Holdings, Inc. | 1.3 bn | 33.8 | 11.6% | 5.6% | +7.5% | −28% / −4% |
| AVRAnteris Technologies Global Corp. | 596.4 m | — | -75.1% | -4,619.3% | −29.2% | +49% / unavailable |
| COCHEnvoy Medical, Inc. | 549.6 m | — | — | -11,304.8% | +7.1% | +749% / +216% |
| ZJYLJin Medical International Ltd. | 483.7 m | 309.0 | 4.1% | 5.8% | −12.0% | −39% / −87% |
| SMTISanara Medtech Inc. | 297.0 m | — | -147.7% | -29.2% | +19.0% | +55% / −0% |
| INGNInogen, Inc. | 191.6 m | — | -13.1% | -6.9% | +3.9% | +2% / +24% |
| LAKELakeland Industries, Inc. | 88.7 m | — | -19.6% | -14.0% | +15.2% | −41% / −39% |
| NTRBNutriband Inc. | 73.9 m | — | -100.7% | -430.4% | −4.8% | +23% / +140% |
| APTAlpha Pro Tech, Ltd. | 58.6 m | 14.1 | 6.6% | 6.8% | +2.3% | +25% / +17% |
| CLGNCollPlant Biotechnologies Ltd | 54.2 m | — | -117.6% | -484.6% | +360.4% | −81% / −92% |
| MYOMyomo, Inc. | 51.5 m | — | -123.8% | -33.5% | +25.7% | +46% / −58% |
| MLSSMilestone Scientific Inc. | 29.2 m | — | -121.7% | -44.0% | +4.0% | +6% / −61% |
| LFWDLifeward Ltd. | 17.2 m | — | -225.6% | -141.3% | −14.1% | −13% / −90% |
| CUPRCuprina Holdings (Cayman) Limited | 14.1 m | — | -1,115.0% | -9,366.7% | +9.2% | −64% / unavailable |
| BBLGBone Biologics Corporation | 1.2 m | — | -47.5% | — | 0.0% | −77% / −98% |
1- and 3-year price returns: for ENOV from daily closes (the same as the performance table), for the other companies from month-end closes.
olivLaw engine forecast
The world engine ran after the company's latest material disclosure. Probabilities are of TOUCHING a level within the horizon (not closing there) and sit next to the random walk (p_rw), the no-information benchmark.
The engine has no published run for this company yet.
Valuation scenarios (editable assumptions)
Illustrative scenarios
Illustrative: not forecasts and without probabilities. Each case is one coherent set of assumptions, computed on today's figures.
Estimated price (USD)
| Estimated price | Bear | Base | Bull |
|---|---|---|---|
| 1 years | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable |
| 3 years | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable |
| 5 years | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable |
AI analysis
AI-generatedAI-generated analysis (Claude) from cited public sources; it may contain errors. Not investment advice. As of 27 Oct 2026 · Model: claude-haiku-5-5.
In brief
Enovis is a medical technology company that designs and distributes orthopedic devices, from prevention and recovery products to implants for reconstructive joint surgery. The company is in a restructuring phase after goodwill impairments in 2025, and first-half 2026 shows a modest sales recovery with annual revenue guidance reaffirmed at about 2.33 billion USD.
SWOT
Strengths
- A diversified portfolio spanning prevention to implants, with a growing Recon segment recognized for innovation.
- Solid international presence, with a significant share of sales from Europe and Asia-Pacific.
- The internal EGX management system, which management regards as a primary competitive advantage.
Weaknesses
- Significant goodwill impairments in 2025 that affected reported results and total capitalization.
- Substantial debt and credit restrictions that limit operational flexibility.
- The P&R segment has lower margins and declined on a reported basis in the second quarter of 2026.
Opportunities
- Growth in joint implants and new product launches could expand share in existing markets.
- Integrating recent acquisitions could bring operational synergies if completed on time.
- Expansion into emerging markets could support long-term growth.
Threats
- Large competitors with superior financial and marketing resources could pressure prices and share.
- Trade tariffs and raw material cost inflation could reduce margins.
- Geopolitical tensions and global economic instability could affect demand and supply chains.
Risks
- Goodwill impairmenthigh
Further goodwill impairments could arise if reporting unit performance declines or the share price stays depressed, affecting reported results.
- Debt and credit covenantshigh
The credit agreement imposes limits on debt, mergers and dividends, and a breach could allow lenders to require immediate repayment.
- Tariffs and supply costsmedium
Tariffs and trade measures could raise raw material costs and limit sourcing options, affecting margins.
- Acquisition integrationmedium
Integrating acquired businesses may face operational, internal control and key-staff retention difficulties, which could reduce expected synergies.
- Manufacturing disruptionlow
A disruption at one of the manufacturing facilities, from equipment failure, natural disaster or other events, could affect the ability to meet demand.
Investment thesis
What would need to be true (bull case)
- If the Recon segment keeps growing through innovation and new launches, and the 2026 guidance holds, the company could show a return to growth and margin improvement.
- If the recent acquisitions are integrated effectively, synergies could support medium-term profitability.
- If debt declines and free cash flow rises, financial flexibility could gradually return.
What would break the thesis
- If competitive pressure in Recon intensifies, larger rivals with superior resources could limit Enovis's growth and market share.
- If tariffs and cost inflation persist, margins could remain under pressure, especially in P&R.
- If further goodwill impairments occur, reported results and total capitalization could be hit again.
What to watch
- Delivery of the 2026 guidance for revenue and adjusted EBITDA2026
- Organic growth trajectory of the P&R segmentQ3 2026
- Impact of tariffs and raw material costs on gross marginnext 10-K
- Acquisition integration and realization of synergies2027
Products, market & competition
AI-generatedAI-generated analysis (Claude) from cited public sources; it may contain errors. Not investment advice. As of 27 Oct 2026 · Model: claude-haiku-5-5.
The business
Enovis Corporation is a medical technology company focused on clinically differentiated solutions aimed at better patient outcomes, with devices used in reconstructive surgery, rehabilitation, pain management and physical therapy 1. Its products cover the continuum of care, from injury prevention and post-surgery rehabilitation to degenerative disease, and it aims to help patients regain or maintain natural motion 1. Operations are run through its internal EGX management system, which management regards as a primary competitive strength 1. In 2025 the company completed seven small acquisition transactions, and in 2026 quarterly results show growth in the Reconstructive segment and 5% organic growth 13.
The company reports two segments: Prevention & Recovery (P&R), which sells bracing, hot and cold therapy, bone growth stimulators, vascular systems and physical therapy products, and Reconstructive (Recon), which sells joint implants for hip, knee, shoulder, elbow, foot and ankle 1. Recon carries higher gross margins than P&R, and its share of sales rose from 37% in 2023 to 49% in 2025, mainly due to the Lima acquisition 1. About 42% of fiscal 2025 sales came from outside the U.S., mostly in Europe and to a lesser extent Asia-Pacific 1.
Sales typically peak in the fourth quarter, and principal raw materials include EVA foam for P&R products and cobalt-chromium, titanium and stainless-steel alloys for Recon implants 1. Tariffs introduced by the U.S. government in 2025 have increased input costs and may keep doing so, which makes supply chain management relevant 1.
Segments
Prevention & Recovery (P&R)
The P&R segment includes orthopedic bracing, thermal therapy, stimulators and physical therapy products sold to specialists and retail consumers, with about 67% of segment revenue generated in the U.S. 1. The segment accounted for 51% of fiscal 2025 sales and has lower gross margins than Recon 1.
Reconstructive (Recon)
The Recon segment offers implants and instrumentation for primary and revision joint replacement, limb reconstruction and foot and ankle procedures, supported by digital surgical planning tools 1. Recon accounted for 49% of fiscal 2025 sales and grew 8% on a reported basis in the second quarter of 2026, making it the main growth driver 13.
Market context
The company operates in orthopedic medical device markets described as highly competitive and fragmented, where the main factors are innovation for better patient outcomes, product quality, reliability, brand and price 1. The implant market is described as fast-growing, and Enovis positions itself as an innovation leader in it 23.
The macro environment is a source of uncertainty: inflationary pressure, geopolitical tensions and trade policy could affect demand and costs, and management expects a more dynamic environment in the second half of 2026 13. Rising energy costs in Europe are a factor that could weigh on margins 2.
Trends
- Acquisitions and Lima integrationmixed
The Lima acquisition, completed in January 2024, brought digital platforms and customized implants into Recon, and integration remains a test for the pace of growth; if integration succeeds, it could support international expansion 12.
- Implant innovationtailwind
New product launches are described as an important driver of Recon growth, and innovation is the main competitive criterion in orthopedics, which can support the company's position 13.
- Inflationary pressure and tariffsheadwind
Higher raw material prices and U.S. tariffs can raise input costs and limit sourcing flexibility, which could reduce margins if prices cannot be passed on to customers 12.
- Interest costs and debtmixed
High debt and credit agreement restrictions limit financial flexibility, but lower financing costs as debt declines could support profitability 12.
Competitive position
In P&R the company names Össur and Breg, Inc. as key competitors, and in Recon it names Stryker, Zimmer Biomet and DePuy Synthes, the medical device business of Johnson & Johnson 1. Recon competitors are described as having far greater financial and marketing resources than Enovis, which makes competition demanding 1.
Enovis argues it can compete effectively because of its innovation history, broad product range and multiple distribution channels, but pricing latitude and the adoption pace of new products remain factors to watch 13.
- StrykerSYK
Key competitor in Recon implants, named in the company's filings.
- Zimmer BiometZBH
Key competitor in Recon implants, named in the company's filings.
- DePuy Synthes (Johnson & Johnson)
Medical device unit of a large group, named as a Recon competitor.
- Össur and Breg, Inc.
Competitors named for P&R bracing and recovery products.
Links, dependencies and risks
Who the company is tied to, from its own SEC filings (customers, suppliers, production, partners, competitors, countries, regulation), from the 5 %+ holders' statements (13D/13G) and from what other companies say about it. Click a node for its evidence; on a listed company the graph moves to it.
Loading the links…
News & filings
In the press
- Enovis inks eCential takeover to develop surgical ortho robotsYahoo Finance — News · 02 Sept 2026 · EN
SEC filings
- Current report01 Sept 2026Regulation FD disclosure · Financial statements and exhibits
- Quarterly report06 Aug 2026
- Current report06 Aug 2026Results of operations · Financial statements and exhibits
- Current report19 May 2026Departure or appointment of officers · Shareholder vote · Financial statements and exhibits
- Quarterly report07 May 2026
- Current report07 May 2026Results of operations · Financial statements and exhibits
- Proxy statement06 Apr 2026
- Annual report26 Feb 2026
- Current report26 Feb 2026Results of operations · Financial statements and exhibits
- Current report12 Jan 2026Regulation FD disclosure · Financial statements and exhibits
Sources
- [1] Form 10-K, fiscal year ended 2025-12-31 · SEC / Enovis Corporation · 26 Feb 2026
- [2] Form 10-Q, quarter ended 2026-07-03 · SEC / Enovis Corporation · 06 Aug 2026
- [3] Form 8-K, results release (exhibit 99.1) · SEC / Enovis Corporation · 06 Aug 2026
Figures computed by olivLaw from SEC filings and closing prices; the qualitative analysis is AI-generated from cited sources. Not investment advice.